Does quitting lower oesophageal-cancer risk for both main types?

01

‘Oesophageal’ names the organ, not the cell type

The oesophagus carries food from the throat to the stomach. Its two main cancer types are squamous-cell carcinoma, arising in the flat lining cells, and adenocarcinoma, arising in glandular cells and commonly found in the lower oesophagus. They are different histological types, not early and late stages of the same cancer.

Tobacco and alcohol are important in squamous-cell risk. Reflux, Barrett's oesophagus and obesity also feature in adenocarcinoma risk information. That does not make smoking irrelevant to adenocarcinoma. Nor can heartburn, a smoking history or the location of discomfort tell you which type you have—or whether you have cancer at all.

[4][5]

02

Why a ‘five-year’ headline loses information

Wang and colleagues' 2017 review pooled observational studies, mostly case–control studies. For time since cessation, its results use the four non-overlapping categories shown below. Every estimate compares former with current smokers, not with never-smokers. A relative risk of 0.59 means a group estimate 0.59 times the reference, not a 59% chance of cancer and not 41 percentage points removed from your own risk.

The squamous-cell estimates show a clearer time pattern. The adenocarcinoma estimates are less precise: each interval in this table includes 1.00, the no-difference reference. That is uncertainty, not proof that quitting has no benefit for adenocarcinoma. Nor does the early squamous-cell interval prove that quitting is useless for five years. These are different groups with different histories, not repeated measurements of one person's recovery.

This is not the latest review. Teshima and colleagues' July 2026 synthesis includes newer research and reports former- and current-smoker comparisons with never-smokers, alongside a fitted cessation-time model. Its broad model combines histological types; included cohort outcomes also cover incidence and mortality. It cannot be substituted for a precise adenocarcinoma-only timetable. Different comparators, outcomes and analyses help explain different headlines. Recall of exposure, health-related quitting, residual confounding and substantial variation between studies still limit precision.

[2][3]

03

Use the comparison to ask a better question—not to clear a symptom

Before keeping a number, ask: which cell type, which outcome, which comparison group, and measured categories or a fitted model? ‘Half the risk’ without those details is incomplete. None of these group estimates tells you an absolute personal probability, guarantees a never-smoker level or determines survival after an existing diagnosis.

Difficulty or pain with swallowing, or unexplained weight loss, deserves qualified medical assessment rather than waiting for a cessation anniversary. Such symptoms have other possible causes and do not establish cancer. If already diagnosed, discuss treatment, symptoms and cessation support with your care team. In England, NHS information points to local stop-smoking support; elsewhere use the relevant local service. This page takes no symptom, smoking-history or quit-date inputs and performs no risk calculation.

[1][2][3][6][7]

04

What to keep in mind

• An overall oesophageal finding is not automatically a type-specific clock.
• An interval including 1 signals uncertainty, not proof of zero benefit.